Dr. Guitart and his colleagues will identify validate and supply banked lesional skin samples or DNA derived from these samples from 100 patients with early stage CTCL for these studies designed to confirm HTS is a better diagnostic test for CTCL (Aim 1) and samples from 34 early stage patients who did not progress and 34 patients who did develop progressive disease for the prognostic studies described in Aim 2. Dr. Guitart will also participate as a consultant expert dermatopathologist, providing expert advice on the pathology of difficult cases.
|Effective start/end date||9/1/20 → 5/31/25|
- Brigham and Womens Hospital (123941//1U01CA253190-01)
- National Cancer Institute (123941//1U01CA253190-01)